Search
for
Sort by
Research 30 of 1000+
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
- Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
- 3D organotypic skin models recapitulate autoantibody-driven pemphigus pathomechanisms and targeted therapeutic response
- Cutaneous adverse effects of targeted therapies
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Dermatologic Reactions to Targeted Therapy
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- The management of EGFR inhibitor adverse events: a case series and treatment paradigm
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- “Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- 1338 Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction
- ISID1338 - Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction